INTRODUCTION
Femoral head avascular necrosis (FHAVN) is the result of irreversible anoxia of the subchondral bone. FHAVN is one of the increasing common causes of musculoskeletal disability that poses a major diagnostic and therapeutic challenge. With approximately 20,000 new reported cases each year, it is the underlying disease in as many as 10% of 500,000 total hip metabolic diseases (Gaucher's disease, hypercholesterolemia, pregnancy, chronic renal failure, hyperparathyroidism, and Cushing's disease), autoimmune diseases, chronic pancreatitis, Caisson's disease, radiation, congenital hip dislocation, and use of potent intravenous bisphosphonates. [4] [5] [6] Various pathophysiologic mechanisms have been proposed to explain the occurrence of FHAVN in these diverse conditions. [4, 7] The proposed mechanisms of cell death include some form of arterial or venous insufficiency or extravascular compression in the context of a rigid bony compartment. [8] Avascular necrosis (AVN) is characterized by areas of dead trabecular bone and marrow that extend to involve the subchondral plate. Typically, the principal weight bearing region, the anterolateral aspect of the femoral head is involved, but any region of the femoral head may be involved.
Measures to preserve the joint are associated with better prognoses when the diagnosis of FHAVN is made early in the course of the disease. The results of joint replacement therapy are poorer in younger age groups than in older patients. It is, therefore, critical to diagnose this condition as early as possible to prevent or delay progression of the disease.
Noninvasive diagnostic tests used in detecting AVN include radiography, three-phase bone scintigraphy (TPBS) with or without single photon emission computed tomography/computed tomography (SPECT/CT), conventional CT scan, and magnetic resonance imaging (MRI).
Tc-99m methylene diphosphonate (MDP) bone scintigraphy could be an ideal modality for assessing the reparative processes of osteonecrosis as the radionuclide activity reflects osteoblastic activity and blood flow. On planar scintigraphic images, the boundary of the necrotic lesion typically appears as a margin of increased tracer uptake adjacent to a photopenic area. [9] However, if the necrotic lesion is small or eccentrically located, it becomes difficult to detect the scintigraphic changes around the necrotic lesion. Thus, planar scintigraphic images suffer from important limitations such as poor spatial resolution and inability to quantify the lesion. Although SPECT, a technique involving three-dimensional scintigraphy, has been developed as a means of overcoming the limitations of planar scintigraphic images, the lack of anatomical detail makes it difficult to use often the information reliably. [10] Uptake of F-18 fluoride, like that of Tc-99m MDP, depends on regional blood flow and osteoblastic activity. However, positron emission tomography (PET) offers superior spatial resolution, and the favorable pharmacokinetic characteristics of F-18 fluoride make this a more sensitive modality than SPECT/CT. Since PET/CT provides both structural and functional information, it has been proven useful for interpreting radionuclide uptake not only in patients with malignancies but also in nonmalignant conditions. [11] Also, PET/CT provides an accurate evaluation of the site of the lesions with the CT part of the PET providing anatomical details. [11] However, to the best of our knowledge, there are no studies to date showing the utility of F-18 fluoride PET/CT bone scan in the diagnosis of FHAVN.
The purpose of this study was to assess the utility of F-18 fluoride PET/CT bone scan in the diagnosis of FHAVN and compare it with MRI.
PATIENTS AND METHODS

Patients
The study was approved by the Institute Ethics Committee. All patients gave written informed consent before inclusion in the study. Exclusion criteria included pregnancy, severe debilitation, contraindication to MRI, and refusal to give written informed consent.
Fifty-one consecutive patients (39 male, 12 female) aged 17-48 (mean 32.5) years with high clinical suspicion of FHAVN and referred for MRI from a Tertiary Orthopedic Care Unit were prospectively evaluated. Clinical assessments done in all the patients were recorded. All patients underwent MRI and F-18 fluoride PET/CT bone scans within 4-10 (mean 8) days of each other.
Image acquisition and analysis
All patients underwent MRI on a 3.0 T (GE Discovery MR750w) MRI unit with a body phased array coil. The following sequences were used: T1 -Axial, sagittal, and coronal (TR/TE, 717/9.2), T2 FS-axial and coronal (TR/TE, 4528/102), PDFS-coronal (TR/TE, 275/30), 1FS-coronal (TR/TE,576/9.2). Ficat staging was used to stage FHAVN on MRI [ Table 1 ]. One experienced radiologist (PS) and one experienced orthopedic surgeon (RKS) read and staged the MRI images.
PET/CT (diagnostic CT) of the pelvis (including both hip joints) was performed 1 h after intravenous injection of 370 MBq of F-18 fluoride on a dedicated PET/CT scanner (Discovery STE 16; GE Healthcare, USA). Reconstruction of the acquired data was performed so as to obtain fused PET/CT images in transaxial, coronal, and sagittal views. Two patients with history of long-term steroid use for systemic lupus erythematosus (SLE), with pain in multiple joints underwent total body PET/CT. Two experienced nuclear medicine physicians (AB, BRM) blinded to the MRI reports read the PET/CT scans separately. Regions of interest (ROIs) were drawn separately over the photopenic area, and the entire head of the affected femur -and the maximum standardized uptake values (SUVmax) of each of these were recorded. In patients with unilateral FHAVN, the SUVmax value of the contralateral (normal) femoral head was also recorded. All patients were followed up clinically for a mean period of 10 months (range: 7-18 months). A final diagnosis of FHAVN was made by surgical pathology or clinical and radiologic follow-up. Two patients with a history of long-term steroid use for SLE and pain in multiple joints underwent total body PET/CT. In addition to bilateral FHAVN, one patient showed AVN of both humeri and the other showed AVN of the right distal end of the femur.
Statistical analysis
DISCUSSION
FHAVN is a disease process for which progression is difficult to predict due to the varying etiology. However, despite the various causes, the end result is often the same. Delayed intervention in undiagnosed FHAVN leads to degenerative arthritis and eventual collapse of the femoral head, making early diagnosis crucial. Noninvasive diagnostic tests used in detecting AVN include plain radiography, CT, MRI, TPBS, and SPECT/CT.
On radiography, abnormal findings in AVN include the "crescent sign" (horizontal subchondral fracture line), cystic or sclerotic change in the femoral head, abnormal contours of the femoral head, and collapse or secondary degenerative change. However, the sensitivity of plain radiography for detecting early stages of the disease is as low as 41%. Normal radiographic findings do not necessarily mean that disease is not present. [12] Ruland et al. demonstrated the sensitivity of Tc-99m MDP in demonstrating the absence of uptake in viable osteocytes by 72 h. They showed that initially a "cold" area is noted in the femoral head, indicating avascularity and reduced delivery of the radiopharmaceutical. There may be a "doughnut" appearance, with a photopenic center surrounded by a region of hyperemia f a e and reactive change. Subsequently, the photopenic area diminishes as there is ingrowth of osteoblasts upward from the metaphysis into the femoral head so that ultimately, as healing progress, there will be uniform intense radioactivity throughout. [13] Using a 1.5 T magnet, Beltran et al. reported 88% sensitivity, 100% specificity, and 94% accuracy with MRI and 78% sensitivity, 75% specificity, and 76% accuracy with bone scintigraphy. [14] A few studies have demonstrated the utility of SPECT in the diagnosis of AVN. SPECT scanning provides images of the radioactivity within the target organ in three dimensions. With this modality, overlying and underlying areas of radioactivity may be separated into sequential tomographic planes, thus providing increased image contrast and improved lesion detection and localization, as compared with planar scintigraphy. Initially, SPECT images reflect vascular integrity. Early in the disease, SPECT scans may demonstrate an avascular focus, which may be missed on MRI unless contrast is used. Collier et al. found a sensitivity of 85% for SPECT scanning. [15] With triple-head high-resolution SPECT scanning, Lee et al. reported a sensitivity of 97%. [12] Ryu et al. compared the diagnostic sensitivity of Tc-99m MDP bone SPECT and MRI in the early detection of femoral head osteonecrosis after renal transplantation and showed a sensitivity of 100% (32/32) for SPECT and only 66% for MRI. [16] Luk et al. evaluated a total of 22 patients and 24 symptomatic hips out of which seven hips (29%) were confirmed to have AVN and showed additional value of SPECT/CT versus SPECT in the diagnosis of FHAVN. They concluded that SPECT/CT conferred a benefit of improvement of area under curve in receiver operating characteristic in the diagnosis of hip AVN compared with SPECT alone. [10] The reported sensitivity of MRI for early diagnosis of osteonecrosis ranges between 88% and 100%. [17] [18] [19] In the early stages of the disease, there may not be any alteration of the normal signal intensity of the femoral head. The first sign of AVN is nonspecific: Diffuse areas of decreased signal intensity are seen in the normally high-signal-intensity fatty marrow on T1W images. This is thought to be due to edema within the marrow. Hence, there are chances that early AVN may be missed in MRI.
While previous studies have demonstrated the utility of TPBS and SPECT in the diagnosis of AVN, there are not many studies using SPECT/CT for detecting AVN. Thus, the reported sensitivity and specificity of bone scintigraphy in the diagnosis of AVN in the literature is either lower or comparable to MRI.
An earlier case report has described the use of F-18 fluoride PET/ CT in the diagnosis of FHAVN. [20] PET has better spatial resolution than SPECT (5 mm vs. ~1 cm respectively). The photopenic area in the affected femoral head is better appreciated on PET. F-18 fluoride has favorable kinetics such as faster blood clearance and 2-fold higher uptake in bone compared to Tc-99m MDP. It has higher capillary permeability and faster blood clearance, which results in better target to background ratio compared to MDP. Also, the high spatial resolution and contrast resolution of the CT component of PET/CT provides morphologic identification. CT scanning is appropriate in evaluating the extent of involvement, such as subchondral lucencies and sclerosis during the reparative stage, before the onset of femoral head collapse and superimposed degenerative disease. CT scanning also defines the extent of disease at Stages II and higher better than MRI and plain film radiography. With multiplanar reconstruction, CT scanning enables detection of subchondral or cancellous fractures and collapse. [12] Thus, hybrid PET/CT improves the sensitivity and specificity compared to PET alone. However, F-18 fluoride PET/ CT has slightly higher radiation dosimetry than Tc-99m MDP. The estimated radiation dose in adult humans is 0.19 mGy/MBq compared to 0.03 mGy/MBq from Tc-99m MDP for the bladder wall and 0.0120 mGy/MBq compared to 0.035 mGy/MBq for the bone surfaces. [21] The final choice of MDP SPECT/CT or 18F-NaF PET/CT would depend, to a large extent, on availability as well as costs involved. The dynamics of NaF allow for more rapid imaging (within 1 h of tracer injection) as compared to Tc-99m MDP allowing higher throughput in departments with high patient turnover. Imaging time with PET/CT is also much shorter compared to SPECT/ CT. As PET/CT provides better image resolution and allows for semi-quantitative analysis, F-18 fluoride PET/CT may be the preferred investigation in the diagnosis of FHAVN. While dynamic phase PET/CT may provide important information on femoral head vascularity, the increased scan duration may be perceived as a drawback. The results of this study suggest that the 1-h static PET/CT image may be useful for a rapid evaluation of FHAVN. While the additional cost and radiation exposure of NaF PET/CT (compared to MDP SPECT/CT) may limit the use of this investigation, the accurate diagnostic information obtained would tend to justify the use of this investigation, especially in postoperative patients with orthopedic hardware. The cost will be significantly lower for institutes equipped with a medical cyclotron since no additional radiopharmaceutical preparation is required.
In the present study, PET/CT showed higher sensitivity and accuracy compared to MRI. PET/CT has the advantage of detecting abnormalities at multiple sites without increasing the cost. It can also be considered when a patient complains of pain at multiple bone and joint areas. In our study, PET/CT could diagnose additional sites of AVN in two patients. Quantitative bone scanning provides physiologic data that cannot be obtained with other modalities, including MRI and SPECT; for example, this technique allows quantification of uptake, which can be used for prognostic purpose.
MRI cannot be performed in patients with cardiac pacemakers or when intracranial clips are present and is challenging in patients with claustrophobia. It is difficult to detect FHAVN after surgery using orthopedic hardware, which creates significant image distortion. F-18 fluoride PET/CT can also be performed when results of MRI are indeterminate.
Limitations of the study
The study group included patients with high suspicion of FHAVN referred from a tertiary orthopedic care, which might have increased the sensitivity of the study. Also, histopathology, which is gold standard in the diagnosis of AVN could not be obtained in all the cases, as it is invasive.
CONCLUSION
F-18 fluoride PET/CT showed good agreement with MRI in the initial diagnosis of FHAVN. It can be especially useful in detecting early disease and also in patients in whom MRI is contraindicated.
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